Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.

Frontiers in immunology - 1 Jan 2021

Tilly Gaëlle, Cadoux Marion, Garcia Alexandra, Morille Jérémy, Wiertlewski Sandrine, Pecqueur Claire, Brouard Sophie, Laplaud David, Degauque Nicolas

Abstract excerpt

Background and Objectives: Inhibition of de novo pyrimidine synthesis in proliferating T and B lymphocytes by teriflunomide, a pharmacological inhibitor of dihydroorotate dehydrogenase (DHODH), has been shown to be an effective therapy to treat patients with MS in placebo-controlled phase 3 trials. Nevertheless, the underlying mechanism contributing to the efficacy of DHODH inhibition has been only partially...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD8-Positive T-Lymphocytes
Share to Hydroxybutyrates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunologic Memory

Share to Immunosuppressive Agents

Share to Interferon-gamma

Share to Lymphocyte Activation

Share to Multiple Sclerosis, Relapsing-Remitting

Share to Nitriles

Source

Open in PubMed Open full text

Identifiers

PMID: 34721394
DOI: 10.3389/fimmu.2021.730342
PMCID: PMC8552527

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.PMID 34721394Read ↗

Dynamics of spinal fluid immune cell alterations following cladribine tablet treatment in multiple sclerosisSemantic proximity Read ↗

Analysis of CD4+ CD8+ double-positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions.Semantic proximity Read ↗

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.Semantic proximity Read ↗

Teriflunomide as a Therapeutic Means for Myelin RepairSemantic proximity Read ↗

Low memory T cells blood counts and high naïve regulatory T cells percentage at relapsing remitting multiple sclerosis diagnosisSemantic proximity Read ↗

Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.Semantic proximity Read ↗

Metabolic pathways engaged by antigen-specific T and B cells after SARS-CoV-2 vaccination in multiple sclerosis patients on different immunomodulatory drugs reveal immunosenescence and predict vaccine efficacy.Semantic proximity Read ↗

High-Resolution Expression Profiling of Peripheral Blood CD8+ Cells in Patients with Multiple Sclerosis Displays Fingolimod-Induced Immune Cell Redistribution.Semantic proximity Read ↗

Encephalitogenic and Regulatory CD8 T Cells in Multiple Sclerosis and Its Animal ModelsSemantic proximity Read ↗

Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients.Semantic proximity Read ↗

Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosisSemantic proximity Read ↗

Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.